Minakem-flap
Minakem-flap

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): FAP-Activated Doxorubicin prodrug

            Therapeutic Area: Oncology Product Name: AVA6000

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable February 18, 2021

            Details:

            In AVA6000, doxorubicin has been modified with Avacta’s pre|CISIONTM chemistry, which renders the modified drug inactive in the circulation until it enters the tumour micro-environment.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Sulforaphane,Alpha-Cyclodextrin

            Therapeutic Area: Oncology Product Name: SFX-01

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: Undisclosed

            Deal Size: $15.3 million Upfront Cash: Undisclosed

            Deal Type: Public Offering February 02, 2021

            Details:

            The net proceeds of the Fundraising are intended to be used to complete the formulation and scale up manufacturing of SFX-01 and other R&D nd general corporate purposes.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Sulforaphane

            Therapeutic Area: Oncology Product Name: SFX-01

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 21, 2021

            Details:

            The data generated for SFX-01 in standard pre-clinical models and orthotopic models (where glioma cells are implanted in brain tissue representing a more disease-relevant model) show tumour shrinkage and significantly extended survival times.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Pro-doxorubicin

            Therapeutic Area: Oncology Product Name: AVA6000

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: Point Biopharma

            Deal Size: $17.5 million Upfront Cash: Undisclosed

            Deal Type: Licensing Agreement January 07, 2021

            Details:

            The agreement provides POINT with an exclusive license to the pre|CISION technology for use AVA6000 Pro-doxorubicin the company intends to develop, and a non-exclusive license to the pre|CISION™ platform to develop broader pipeline of FAP-activated radiopharmaceuticals.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): FAP activated doxorubicin prodrug

            Therapeutic Area: Oncology Product Name: AVA6000

            Highest Development Status: Preclinical Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable December 23, 2020

            Details:

            The dose-escalation phase of the study, which will be carried out in 15-20 patients, is designed to evaluate the safety of AVA6000 in humans and establish the appropriate dosing levels for the dose expansion phase of the study.